

PhageVax, Inc.™ debrief from Dr. Dale VanderPutten, Co-founder and Board Member regarding his testimony during: "The Administration's Plans to Develop and Distribute the Novel Influenza A (H1N1) Vaccine" held at the Rayburn House Office Building on June 22nd, 2009.

Rep. Edolphus Towns (D-NY), Chairman of the House Committee on Oversight and Government Reform and Ranking Member Rep. Darrell E. Issa (R-CA) had invited PhageVax, Inc. (PVI) to brief the committee's Members & Staff on the company's Bacteriophage-DNA vaccine (aka "Phage") technology for manufacturing (multi-type) Pandemic Influenza Vaccines. PVI can rapidly manufacture vaccines against unforeseen viruses, all types of bacteria as well as parasites, such as malaria.

Representatives of GSK®, MedImmune®, Sanofi Pasteur® and Novartis® were also invited to brief the committee.

GSK, MedImmune, Sanofi Pasteur and Novartis discussed the status of manufacturing of H1N1 vaccine in their commercial facilities and while none wished to be pinned down on timelines the consensus was that vaccine would be available in the fall of '09 but probably later than the delivery of seasonal flu vaccine. MedImmune pointed out that their vaccine is live attenuated and as such has some efficacy advantages over traditional flu vaccine. GSK, Sanofi Pasteur and Novartis all discussed the potential utility of adjuvants but acknowledged that the approval path for "adjuvantized" (aka "antigen-sparing") flu vaccine is unclear. MedImmune pointed out that their vaccine requires no adjuvant. The committee staff and others in a attendance asked questions regarding availability USA vs. foreign manufacture and release testing mostly routine technical information. All presenters discussed mammalian cell-based manufacture vs. egg-based and their relative progress with each technology.

Dr. Dale VanderPutten presented the PhageVax, Inc. Bacteriophage-DNA technology for manufacturing pandemic flu vaccine pointing out the design of the process is specific for rapidly emerging infectious diseases and as such is better suited for pandemic flu than is seasonal flu manufacture processes.

He noted the timeline for Bacteriophage-based DNA vaccine manufacture fits with the Los Alamos Nat'l Labs [See this document for download at: www.PhageVax.com] prediction of pandemic spread in the US and noted that had the PhageVax, Inc. vaccine technology been funded appropriately (in the past), that we (PhageVax, Inc.) would have millions of vials filled and labeled ready for release at the time of this meeting [6-22-09]; not maybe sometime in the fall and as such it is a "paradigm shift" reducing manufacturing time from months to weeks.

Dr. VanderPutten presented the "mouse data" on "H5N1 Avian Influenza" immunization [which was documented by the company on July 24th, 2006] where PhageVax, Inc. produced an H5N1 HPAI Bacteriophage-DNA Vaccine, shot said vaccine into mice and tested for "Immunoreactivity". The Doctor also noted that Phage is "self adjuvantizing"™.

Dr. VanderPutten pointed out that "Cell-based" manufacture, while having some advantages over "Egg-based" manufacture, still does not fit with the Los Alamos time-lines and that PhageVax, Inc. can vial millions of doses of vaccine by the time cell based manufacturers receive their "reference strains" from CDC or WHO.

He also pointed out that cell based manufacture is Omnia Biologics' every day business [Note: Dr. VanderPutten is CEO of Omnia Biologics, as well] and there is a role for cell-based manufacturing in vaccine production but it is "inappropriate" for pandemic flu. He ended by asking the House Committee on Oversight and Government Reform for a fair chance to demonstrate the advantages of the company's Bacteriophage-DNA vaccine (aka "Phage") technology in the clinic.

The PhageVax, Inc. presentation was well received but it is important to note that said Committee's primary interest was in the progress of vaccine manufacture for the current novel H1N1 Pandemic and that the PhageVax, Inc. technology would not be FDA "Fast Track" approved in time to address, at least the 1st Wave of said Pandemic.

CEO Statement: It is not too late to gain US Government Cooperation to address the 2nd Wave and/or the 3rd Wave of this Influenza Pandemic. New personnel are now and will be heading the important subordinate positions under HHS Sec. Sebelius.

With continuous Congressional Oversight and HHS Cooperation, the company should be able to satisfy the US Tax-payers' need for "multi-type" Influenza Vaccines within the Fall 2009 time-frame. Please see the other two (2) documents (for download) at: www.PhageVax.com

Clark Tibbs, CEO ***PhageVax, Inc.*** CCR CAGE CODE: 4M4V6
Phone: 740.366.9013 Fax: 740.366.5230 Cell: 740.502.9010
E-mail: Clark@PhageVax.com -or- VHO@roadrunner.com -or- CTA@ee.net
General Offices & HQ: 855 Sharon Valley Road, Suite 101 Newark, Ohio 43055-2860 USA